Major Advances in Psychiatry Transform Care in 2025

The year 2025 marked significant advancements in psychiatry, highlighted by the US Food and Drug Administration’s (FDA) approvals of several innovative treatments. Among these, the approval of esketamine as a monotherapy for adults with treatment-resistant depression stands out, offering a crucial option for patients who do not respond to traditional oral antidepressants. This was announced on January 21, 2025, following extensive Phase 4 trials that demonstrated rapid and substantial improvements in depressive symptoms.

The FDA also cleared BrainsWay Ltd’s Deep Transcranial Magnetic Stimulation (Deep TMS) system for adolescents aged 15 to 21 with major depressive disorder (MDD) on November 13, 2025. This noninvasive device provides daily 20-minute sessions over a period of 4 to 6 weeks, yielding significant reductions in both depressive and anxiety symptoms, according to real-world data supporting its efficacy.

Significant updates came from Teva Pharmaceuticals, which received FDA approval on October 10, 2025 for UZEDY, a once-monthly, subcutaneous extended-release formulation of risperidone for adults with bipolar I disorder. Utilizing SteadyTeqTM technology, UZEDY ensures controlled drug release, addressing previous treatment gaps and enhancing patient adherence.

The FDA also expanded the use of Indivior’s SUBLOCADE, a buprenorphine extended-release injection for opioid use disorder, on February 24, 2025. The updates to its labeling allow for additional injection sites and streamline the induction process to a single dose with one-hour observation, thereby promoting more flexible treatment options.

Research has also focused on promising new therapies. Teva Pharmaceuticals submitted a New Drug Application for TEV-749, a once-monthly subcutaneous olanzapine extended-release injection aimed at treating adult schizophrenia. Phase 3 trial data indicated strong efficacy and safety, offering patients a reliable alternative to oral forms of the medication.

In the area of attention-deficit hyperactivity disorder (ADHD), Otsuka Pharmaceuticals is pursuing FDA approval for centanafadine, a novel norepinephrine-dopamine reuptake inhibitor, with Phase 3 trials showing meaningful symptom reduction for patients aged 4 to 55. Similarly, Johnson & Johnson submitted a supplemental New Drug Application for lumateperone (CAPLYTA) to prevent relapse in schizophrenia, supported by data showing a 63% reduction in relapse risk.

Clinical trials also explored innovative treatments for anxiety disorders. A Phase 2b trial conducted by MindMed indicated that a single 100 μg dose of MM120 (LSD) significantly reduced anxiety in adults with generalized anxiety disorder (GAD), with effects sustained for up to 12 weeks.

The intersection of mental health and physical conditions has garnered attention, as patients with psoriasis are 1.5 times more likely to develop depression. Experts like Eva Parker, MD, from Vanderbilt Health, emphasize the importance of routine mental health screening to address both physical symptoms and their emotional impacts.

Additionally, the ethical landscape of psychiatric treatment is evolving. In a recent episode of Medical Ethics Unpacked, hosts Steve Levine, MD, and Dominic Sisti, PhD, discussed the challenges surrounding psychedelic therapies, including issues of consent and cultural integration, alongside dosing and trial considerations.

As the psychiatric field continues to develop new treatments and refine existing ones, the insights shared by experts, such as those from Gus Alva, MD, who hosts The Gus Alva Perspective, play a vital role in guiding clinicians through the latest research and practices.

The advancements witnessed in 2025 not only enhance treatment options but also reflect a broader commitment to improving mental health care, shaping a future where personalized and effective psychiatric care is more accessible than ever.